<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84924731943</prism:url><dc:identifier>SCOPUS_ID:84924731943</dc:identifier><eid>2-s2.0-84924731943</eid><pubmed-id>25495147</pubmed-id><prism:doi>10.1586/14787210.2015.990381</prism:doi><dc:title>The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: Findings and implications</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>27</citedby-count><prism:publicationName>Expert Review of Anti-Infective Therapy</prism:publicationName><dc:publisher>Taylor and Francis Ltdinfo@expert-reviews.com</dc:publisher><source-id>16341</source-id><prism:issn>17448336 14787210</prism:issn><prism:volume>13</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>279</prism:startingPage><prism:endingPage>289</prism:endingPage><prism:pageRange>279-289</prism:pageRange><prism:coverDate>2015-02-01</prism:coverDate><openaccess>0</openaccess><openaccessFlag>false</openaccessFlag><dc:creator><author seq="1" auid="23481795400"><ce:initials>J.</ce:initials><ce:indexed-name>Furst J.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Jurij</ce:given-name><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Fürst J.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Jurij</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23481795400</author-url><affiliation id="100419274" href="https://api.elsevier.com/content/affiliation/affiliation_id/100419274"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>© 2015 Informa UK, Ltd.</publishercopyright><ce:para>Introduction: Rising antibiotic resistance has become an increasing public health problem. There is a well-established correlation between antibiotic consumption and antimicrobial resistance. Consequently, measures to rationalize the prescribing of antibiotics should reduce the resistant strains. Following a 24% increase in antibiotic consumption at the end of the 1990s, multiple activities were designed and introduced by the Health Insurance Institute of Slovenia (ZZZS) and other organizations in Slovenia at the end of 1999. These activities reduced the antibiotic consumption by 18.7% by 2002. These measures have continued. Objective: To study changes in antibiotic utilization from 1995 to 2012 alongside the multiple interventions and their consequences, including changes in resistance patterns. Methods: This was a retrospective observational study involving all patients dispensed at least one ZZZS prescription for an antibiotic in Slovenia. Utilization was expressed in defined daily doses per thousand inhabitants per day. Multifaceted interventions were conducted over time involving all key stakeholder groups, that is, the Ministry of Health, ZZZS, physician groups and patients. These included comprehensive communication programs as well as prescribing restrictions for a number of antibiotics and classes. Results: From 1999 to 2012, antibiotic consumption decreased by 2-9% per year, with an overall decrease of 31%. There were also appreciable structural changes. Overall antibiotic utilization and the utilization of 7 out of 10 antibiotics significantly decreased after multiple interventions. The resistance of Streptococcus pneumoniae to penicillin decreased in line with decreased utilization. However, its resistance to macrolides increased from 5.4 to 21% despite halving of its utilization. The resistance of Escherichia coli to fluoroquinolones doubled from 10 to 21% despite utilization decreasing by a third. Expenditures on antibiotics decreased by 53%. Conclusion: Multiple demand-side measures introduced following increased utilization significantly decreased subsequent antibiotic utilization and associated costs. However, there was variable impact on antibiotic resistance. Additional targeted activities are planned to further reduce antibiotic prescribing and resistance.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84924731943" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84924731943&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84924731943&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60003771" href="https://api.elsevier.com/content/affiliation/affiliation_id/60003771"><affilname>University of Manchester</affilname><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60024724" href="https://api.elsevier.com/content/affiliation/affiliation_id/60024724"><affilname>University of Strathclyde</affilname><affiliation-city>Glasgow</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"><affilname>Univerzitetni Klinični Center Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60019295" href="https://api.elsevier.com/content/affiliation/affiliation_id/60019295"><affilname>Karolinska University Hospital</affilname><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation id="60012937" href="https://api.elsevier.com/content/affiliation/affiliation_id/60012937"><affilname>Universiteit Antwerpen</affilname><affiliation-city>Antwerpen</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation id="100419274" href="https://api.elsevier.com/content/affiliation/affiliation_id/100419274"><affilname>Health Insurance Institute of Slovenia</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="23481795400"><ce:initials>J.</ce:initials><ce:indexed-name>Furst J.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Jurij</ce:given-name><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Fürst J.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Jurij</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23481795400</author-url><affiliation id="100419274" href="https://api.elsevier.com/content/affiliation/affiliation_id/100419274"/></author><author seq="2" auid="6603836145"><ce:initials>M.</ce:initials><ce:indexed-name>Cizman M.</ce:indexed-name><ce:surname>Čižman</ce:surname><ce:given-name>Milan</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Čižman M.</ce:indexed-name><ce:surname>Čižman</ce:surname><ce:given-name>Milan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6603836145</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="3" auid="55365849500"><ce:initials>J.</ce:initials><ce:indexed-name>Mrak J.</ce:indexed-name><ce:surname>Mrak</ce:surname><ce:given-name>Jana</ce:given-name><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Mrak J.</ce:indexed-name><ce:surname>Mrak</ce:surname><ce:given-name>Jana</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55365849500</author-url><affiliation id="100419274" href="https://api.elsevier.com/content/affiliation/affiliation_id/100419274"/></author><author seq="4" auid="56724297600"><ce:initials>D.</ce:initials><ce:indexed-name>Kos D.</ce:indexed-name><ce:surname>Kos</ce:surname><ce:given-name>Damjan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Kos D.</ce:indexed-name><ce:surname>Kos</ce:surname><ce:given-name>Damjan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56724297600</author-url><affiliation id="100419274" href="https://api.elsevier.com/content/affiliation/affiliation_id/100419274"/></author><author seq="5" auid="55617507200"><ce:initials>S.</ce:initials><ce:indexed-name>Campbell S.</ce:indexed-name><ce:surname>Campbell</ce:surname><ce:given-name>Stephen</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Campbell S.</ce:indexed-name><ce:surname>Campbell</ce:surname><ce:given-name>Stephen</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55617507200</author-url><affiliation id="60003771" href="https://api.elsevier.com/content/affiliation/affiliation_id/60003771"/><affiliation id="60003771" href="https://api.elsevier.com/content/affiliation/affiliation_id/60003771"/></author><author seq="6" auid="6701920264"><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname><ce:given-name>Samuel</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname><ce:given-name>Samuel</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6701920264</author-url><affiliation id="60012937" href="https://api.elsevier.com/content/affiliation/affiliation_id/60012937"/></author><author seq="7" auid="7203015121"><ce:initials>L.L.</ce:initials><ce:indexed-name>Gustafsson L.L.</ce:indexed-name><ce:surname>Gustafsson</ce:surname><ce:given-name>Lars L.</ce:given-name><preferred-name><ce:initials>L.L.</ce:initials><ce:indexed-name>Gustafsson L.</ce:indexed-name><ce:surname>Gustafsson</ce:surname><ce:given-name>Lars L.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7203015121</author-url><affiliation id="60019295" href="https://api.elsevier.com/content/affiliation/affiliation_id/60019295"/></author><author seq="8" auid="24329188700"><ce:initials>L.</ce:initials><ce:indexed-name>Furst L.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Luka</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Fürst L.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Luka</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/24329188700</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="9" auid="23466946100"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname><ce:given-name>Brian</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname><ce:given-name>Brian</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23466946100</author-url><affiliation id="60019295" href="https://api.elsevier.com/content/affiliation/affiliation_id/60019295"/><affiliation id="60024724" href="https://api.elsevier.com/content/affiliation/affiliation_id/60024724"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>antibiotic resistance</author-keyword><author-keyword>antibiotic use</author-keyword><author-keyword>drug utilization</author-keyword><author-keyword>multifaceted interventions</author-keyword><author-keyword>policies</author-keyword><author-keyword>rational use of antibiotics</author-keyword><author-keyword>Slovenia</author-keyword></authkeywords><idxterms><mainterm weight="b" candidate="n">Anti-Bacterial Agents</mainterm><mainterm weight="b" candidate="n">Drug Resistance, Microbial</mainterm><mainterm weight="b" candidate="n">Drug Utilization</mainterm><mainterm weight="b" candidate="n">Fluoroquinolones</mainterm><mainterm weight="b" candidate="n">Follow-Up Studies</mainterm><mainterm weight="b" candidate="n">Humans</mainterm><mainterm weight="b" candidate="n">Macrolides</mainterm><mainterm weight="b" candidate="n">Practice Patterns, Physicians'</mainterm><mainterm weight="b" candidate="n">Retrospective Studies</mainterm><mainterm weight="b" candidate="n">Slovenia</mainterm><mainterm weight="b" candidate="n">Streptococcus pneumoniae</mainterm></idxterms><subject-areas><subject-area code="2404" abbrev="IMMU">Microbiology</subject-area><subject-area code="2726" abbrev="MEDI">Microbiology (medical)</subject-area><subject-area code="2725" abbrev="MEDI">Infectious Diseases</subject-area><subject-area code="2406" abbrev="IMMU">Virology</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2019-03-22T18:24:41.573Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type><xocs:funding><xocs:funding-agency-matched-string>Ministry of Health</xocs:funding-agency-matched-string><xocs:funding-agency>Ministry of Health</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100009647</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/3489940/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Karolinska Institutet</xocs:funding-agency-matched-string><xocs:funding-agency-acronym>KI</xocs:funding-agency-acronym><xocs:funding-agency>Karolinska Institutet</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100004047</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/2661886/</xocs:funding-agency-country></xocs:funding><xocs:funding-text>In addition since 1995, the Department of Infectious Diseases of the University Medical Centre Ljubljana has undertaken annual 2-day symposia discussing ways to enhance the appropriate use of antibiotics. Since 2010, a yearly workshop on the rational prescribing of antibiotics has been conducted, which is devoted to young doctors caring for outpatients and inpatients. This workshop is organized by the Slovenian Society of Chemotherapy. Once a year on November 18, ‘Antibiotic Awareness Day’ is observed as part of the European Antibiotic Awareness Day program [43]. This event is organized by the Ministry of Health and the National Committee for the Rational Use of Antimicrobials. Members of the public are informed on the subjects related to the rational use of antibiotics by media, posters and flyers.</xocs:funding-text><xocs:funding-text>groups, knowing how difficult it is to change the behavior of key stakeholders through national projects [57,58]. All activities were based on the national guidelines for the treatment of infectious diseases. These activities were supported by medical societies and engaged medical professionals, members of national bodies at the Ministry of Health and ZZZS’s committee for the reimbursement of medicines.</xocs:funding-text><xocs:funding-text>The report writing was in part funded by a grant from the Karolinska Institutet. J Fürst, J Mrak and D Kos are employed by the Health Insurance Institute of Slovenia. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</xocs:funding-text></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered year="2019" month="08" day="20" timestamp="2019-08-20T07:53:57.000057-04:00"/><ait:date-sort year="2015" month="02" day="01"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2018 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.1586/14787210.2015.990381</ce:doi><itemid idtype="PUI">605222711</itemid><itemid idtype="CAR-ID">637937081</itemid><itemid idtype="EMBASE">2015201218</itemid><itemid idtype="MEDL">25495147</itemid><itemid idtype="SCP">84924731943</itemid><itemid idtype="SGR">84924731943</itemid><itemid idtype="PUIsecondary">610678995</itemid></itemidlist><history><date-created year="2017" month="05" day="03" timestamp="BST 09:21:14"/></history><dbcollection>EMBASE</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword xml:lang="eng">antibiotic resistance</author-keyword><author-keyword xml:lang="eng">antibiotic use</author-keyword><author-keyword xml:lang="eng">drug utilization</author-keyword><author-keyword xml:lang="eng">multifaceted interventions</author-keyword><author-keyword xml:lang="eng">policies</author-keyword><author-keyword xml:lang="eng">rational use of antibiotics</author-keyword><author-keyword xml:lang="eng">Slovenia</author-keyword></author-keywords></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: Findings and implications</titletext></citation-title><author-group><author auid="23481795400" seq="1" type="auth"><ce:initials>J.</ce:initials><ce:indexed-name>Furst J.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Jurij</ce:given-name><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Fürst J.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Jurij</ce:given-name></preferred-name></author><author auid="55365849500" seq="3" type="auth"><ce:initials>J.</ce:initials><ce:indexed-name>Mrak J.</ce:indexed-name><ce:surname>Mrak</ce:surname><ce:given-name>Jana</ce:given-name><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Mrak J.</ce:indexed-name><ce:surname>Mrak</ce:surname><ce:given-name>Jana</ce:given-name></preferred-name></author><author auid="56724297600" seq="4" type="auth"><ce:initials>D.</ce:initials><ce:indexed-name>Kos D.</ce:indexed-name><ce:surname>Kos</ce:surname><ce:given-name>Damjan</ce:given-name><preferred-name><ce:initials>D.</ce:initials><ce:indexed-name>Kos D.</ce:indexed-name><ce:surname>Kos</ce:surname><ce:given-name>Damjan</ce:given-name></preferred-name></author><affiliation afid="100419274" country="svn"><organization>Health Insurance Institute of Slovenia</organization><address-part>Miklošičeva 24</address-part><city>Ljubljana</city><postal-code>SI-1507</postal-code><affiliation-id afid="100419274"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="6603836145" seq="2" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Cizman M.</ce:indexed-name><ce:surname>Čižman</ce:surname><ce:given-name>Milan</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Čižman M.</ce:indexed-name><ce:surname>Čižman</ce:surname><ce:given-name>Milan</ce:given-name></preferred-name></author><affiliation afid="60021479" dptid="113628685" country="svn"><organization>Department of Infectious Diseases</organization><organization>University Medical Centre</organization><address-part>Japljeva 2</address-part><city>Ljubljana</city><postal-code>SI-1525</postal-code><affiliation-id afid="60021479" dptid="113628685"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="55617507200" seq="5" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Campbell S.</ce:indexed-name><ce:surname>Campbell</ce:surname><ce:given-name>Stephen</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Campbell S.</ce:indexed-name><ce:surname>Campbell</ce:surname><ce:given-name>Stephen</ce:given-name></preferred-name></author><affiliation afid="60003771" dptid="103240816" country="gbr"><organization>Centre for Primary Care</organization><organization>Institute of Population Health</organization><organization>University of Manchester</organization><city>Manchester</city><postal-code>M13 9PL</postal-code><affiliation-id afid="60003771" dptid="103240816"/><country>United Kingdom</country></affiliation></author-group><author-group><author auid="55617507200" seq="5" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Campbell S.</ce:indexed-name><ce:surname>Campbell</ce:surname><ce:given-name>Stephen</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Campbell S.</ce:indexed-name><ce:surname>Campbell</ce:surname><ce:given-name>Stephen</ce:given-name></preferred-name></author><affiliation afid="60003771" dptid="114181731" country="gbr"><organization>NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre</organization><organization>University of Manchester</organization><city>Manchester</city><postal-code>M13 9PL</postal-code><affiliation-id afid="60003771" dptid="114181731"/><country>United Kingdom</country></affiliation></author-group><author-group><author auid="6701920264" seq="6" type="auth"><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname><ce:given-name>Samuel</ce:given-name><preferred-name><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname><ce:given-name>Samuel</ce:given-name></preferred-name></author><affiliation afid="60012937" country="bel"><organization>Centre for General Practice and Laboratory of Medical Microbiology</organization><organization>Vaccine and Infectious Disease Institute(VAXINFECTIO)</organization><organization>University of Antwerp-Campus Drie Eiken</organization><address-part>Universiteitsplein 1</address-part><city>Antwerp</city><postal-code>BE-2610</postal-code><affiliation-id afid="60012937"/><country>Belgium</country></affiliation></author-group><author-group><author auid="7203015121" seq="7" type="auth" date-locked="2017-05-18T11:32:22.547"><ce:initials>L.L.</ce:initials><ce:indexed-name>Gustafsson L.L.</ce:indexed-name><ce:surname>Gustafsson</ce:surname><ce:given-name>Lars L.</ce:given-name><preferred-name><ce:initials>L.L.</ce:initials><ce:indexed-name>Gustafsson L.</ce:indexed-name><ce:surname>Gustafsson</ce:surname><ce:given-name>Lars L.</ce:given-name></preferred-name></author><author auid="23466946100" seq="9" type="auth"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname><ce:given-name>Brian</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname><ce:given-name>Brian</ce:given-name></preferred-name></author><affiliation afid="60019295" dptid="113350296" country="swe"><organization>Department of Laboratory Medicine</organization><organization>Division of Clinical Pharmacology</organization><organization>Karolinska University Hospital Huddinge</organization><city>Stockholm</city><postal-code>SE-141 86</postal-code><affiliation-id afid="60019295" dptid="113350296"/><country>Sweden</country></affiliation></author-group><author-group><author auid="24329188700" seq="8" type="auth"><ce:initials>L.</ce:initials><ce:indexed-name>Furst L.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Luka</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Fürst L.</ce:indexed-name><ce:surname>Fürst</ce:surname><ce:given-name>Luka</ce:given-name></preferred-name></author><affiliation afid="60031106" country="svn"><organization>University of Ljubljana</organization><organization>Faculty of Computer and Information Science</organization><address-part>Večna pot 113</address-part><city>Ljubljana</city><postal-code>SI-1000</postal-code><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="23466946100" seq="9" type="auth"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname><ce:given-name>Brian</ce:given-name><preferred-name><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname><ce:given-name>Brian</ce:given-name></preferred-name></author><affiliation afid="60024724" dptid="104246966" country="gbr"><organization>Strathclyde Institute of Pharmacy and Biomedical Sciences</organization><organization>University of Strathclyde</organization><city>Glasgow</city><postal-code>G4 0RE</postal-code><affiliation-id afid="60024724" dptid="104246966"/><country>United Kingdom</country></affiliation></author-group><correspondence><person><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname><ce:given-name>Brian</ce:given-name></person><affiliation country="swe"><organization>Department of Laboratory Medicine</organization><organization>Division of Clinical Pharmacology</organization><organization>Karolinska University Hospital Huddinge</organization><city>Stockholm</city><postal-code>SE-141 86</postal-code><country>Sweden</country></affiliation></correspondence><grantlist complete="y"><grant><grant-acronym>KI</grant-acronym><grant-agency>Karolinska Institutet</grant-agency></grant></grantlist><abstracts><abstract original="y" xml:lang="eng"><publishercopyright>© 2015 Informa UK, Ltd.</publishercopyright><ce:para>Introduction: Rising antibiotic resistance has become an increasing public health problem. There is a well-established correlation between antibiotic consumption and antimicrobial resistance. Consequently, measures to rationalize the prescribing of antibiotics should reduce the resistant strains. Following a 24% increase in antibiotic consumption at the end of the 1990s, multiple activities were designed and introduced by the Health Insurance Institute of Slovenia (ZZZS) and other organizations in Slovenia at the end of 1999. These activities reduced the antibiotic consumption by 18.7% by 2002. These measures have continued. Objective: To study changes in antibiotic utilization from 1995 to 2012 alongside the multiple interventions and their consequences, including changes in resistance patterns. Methods: This was a retrospective observational study involving all patients dispensed at least one ZZZS prescription for an antibiotic in Slovenia. Utilization was expressed in defined daily doses per thousand inhabitants per day. Multifaceted interventions were conducted over time involving all key stakeholder groups, that is, the Ministry of Health, ZZZS, physician groups and patients. These included comprehensive communication programs as well as prescribing restrictions for a number of antibiotics and classes. Results: From 1999 to 2012, antibiotic consumption decreased by 2-9% per year, with an overall decrease of 31%. There were also appreciable structural changes. Overall antibiotic utilization and the utilization of 7 out of 10 antibiotics significantly decreased after multiple interventions. The resistance of Streptococcus pneumoniae to penicillin decreased in line with decreased utilization. However, its resistance to macrolides increased from 5.4 to 21% despite halving of its utilization. The resistance of Escherichia coli to fluoroquinolones doubled from 10 to 21% despite utilization decreasing by a third. Expenditures on antibiotics decreased by 53%. Conclusion: Multiple demand-side measures introduced following increased utilization significantly decreased subsequent antibiotic utilization and associated costs. However, there was variable impact on antibiotic resistance. Additional targeted activities are planned to further reduce antibiotic prescribing and resistance.</ce:para></abstract></abstracts><source srcid="16341" type="j" country="gbr"><sourcetitle>Expert Review of Anti-Infective Therapy</sourcetitle><sourcetitle-abbrev>Expert Rev. Anti-Infect. Ther.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Expert Review of Anti-Infective Therapy</translated-sourcetitle><issn type="electronic">17448336</issn><issn type="print">14787210</issn><codencode>ERATC</codencode><volisspag><voliss volume="13" issue="2"/><pagerange first="279" last="289"/></volisspag><publicationyear first="2015"/><publicationdate><year>2015</year><month>02</month><day>01</day><date-text xfab-added="true">1 February 2015</date-text></publicationdate><publisher><publishername>Taylor and Francis Ltd</publishername><ce:e-address type="email">info@expert-reviews.com</ce:e-address></publisher></source><enhancement><classificationgroup><classifications type="EMCLASS"><classification> <classification-code>17</classification-code> <classification-description>Public Health, Social Medicine and Epidemiology</classification-description> </classification><classification> <classification-code>36</classification-code> <classification-description>Health Policy, Economics and Management</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification></classifications><classifications type="ASJC"><classification>2404</classification><classification>2726</classification><classification>2725</classification><classification>2406</classification></classifications><classifications type="SUBJABBR"><classification>IMMU</classification><classification>MEDI</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>amoxicillin plus clavulanic acid</chemical-name><cas-registry-number>74469-00-4</cas-registry-number><cas-registry-number>79198-29-1</cas-registry-number></chemical><chemical><chemical-name>cotrimoxazole</chemical-name><cas-registry-number>8064-90-2</cas-registry-number></chemical><chemical><chemical-name>lincosamide</chemical-name><cas-registry-number>80738-43-8</cas-registry-number></chemical><chemical><chemical-name>penicillin V</chemical-name><cas-registry-number>87-08-1</cas-registry-number></chemical></chemicals><chemicals source="nlm"><chemical><chemical-name>Anti-Bacterial Agents</chemical-name></chemical><chemical><chemical-name>Fluoroquinolones</chemical-name></chemical><chemical><chemical-name>Macrolides</chemical-name></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="61"><reference id="1"><ref-info><ref-title><ref-titletext>Fighting antibiotic resistance: Marrying new financial incentives to meeting public health goals</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78649695936</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.S.</ce:initials><ce:indexed-name>Kesselheim A.S.</ce:indexed-name><ce:surname>Kesselheim</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Outterson K.</ce:indexed-name><ce:surname>Outterson</ce:surname></author></ref-authors><ref-sourcetitle>Health Aff (Millwood)</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="29" issue="9"/><pagerange first="1689" last="1696"/></ref-volisspag></ref-info><ref-fulltext>Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood) 2010;29(9):1689-96</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>Preserving the lifesaving power of antimicrobial agents</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79952427389</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.M.</ce:initials><ce:indexed-name>Hughes J.M.</ce:indexed-name><ce:surname>Hughes</ce:surname></author></ref-authors><ref-sourcetitle>JAMA</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="305" issue="10"/><pagerange first="1027" last="1028"/></ref-volisspag></ref-info><ref-fulltext>Hughes JM. Preserving the lifesaving power of antimicrobial agents. JAMA 2011; 305(10):1027-8</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>Interventions to improve antibiotic prescribing practices for hospital inpatients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84886995583</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Davey P.</ce:indexed-name><ce:surname>Davey</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Brown E.</ce:indexed-name><ce:surname>Brown</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Charani E.</ce:indexed-name><ce:surname>Charani</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cochrane Database Syst Rev</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="4"/><pagerange first="Cd003543"/></ref-volisspag></ref-info><ref-fulltext>Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4:Cd003543</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007</ref-titletext></ref-title><refd-itemidlist><itemid idtype="ARTNUM">e1000084</itemid><itemid idtype="SGR">67650305509</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>Sabuncu E.</ce:indexed-name><ce:surname>Sabuncu</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>David J.</ce:indexed-name><ce:surname>David</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Bernede-Bauduin C.</ce:indexed-name><ce:surname>Bernede-Bauduin</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>PLoS Med</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="6" issue="6"/></ref-volisspag></ref-info><ref-fulltext>Sabuncu E, David J, Bernede-Bauduin C, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009;6(6):e1000084</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">72149120292</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Huttner B.</ce:indexed-name><ce:surname>Huttner</ce:surname></author><author seq="2"><ce:initials>H.</ce:initials><ce:indexed-name>Goossens H.</ce:indexed-name><ce:surname>Goossens</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Verheij T.</ce:indexed-name><ce:surname>Verheij</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Harbarth S.</ce:indexed-name><ce:surname>Harbarth</ce:surname></author></ref-authors><ref-sourcetitle>Lancet Infect Dis</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="10" issue="1"/><pagerange first="17" last="31"/></ref-volisspag></ref-info><ref-fulltext>Huttner B, Goossens H, Verheij T, Harbarth S. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis 2010;10(1):17-31</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Rationalizing antibiotic use to limit antibiotic resistance in India</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80054728070</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.K.</ce:initials><ce:indexed-name>Ganguly N.K.</ce:indexed-name><ce:surname>Ganguly</ce:surname></author><author seq="2"><ce:initials>N.K.</ce:initials><ce:indexed-name>Arora N.K.</ce:indexed-name><ce:surname>Arora</ce:surname></author><author seq="3"><ce:initials>S.J.</ce:initials><ce:indexed-name>Chandy S.J.</ce:indexed-name><ce:surname>Chandy</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Indian J Med Res</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="134"/><pagerange first="281" last="294"/></ref-volisspag></ref-info><ref-fulltext>Ganguly NK, Arora NK, Chandy SJ, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011;134:281-94</ref-fulltext></reference><reference id="7"><ref-info><refd-itemidlist><itemid idtype="SGR">84924651502</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>WeMeReC Bulletin</ce:indexed-name><ce:surname>WeMeReC Bulletin</ce:surname></author></ref-authors><ref-sourcetitle>Appropriate Antibiotic Use-whose Responsibility?</ref-sourcetitle><ref-website><ce:e-address type="email">www.wemerec.org/Documents/Bulletins/AntibioBulletin2012Online.pdfNovember</ce:e-address></ref-website><ref-text>Available from</ref-text></ref-info><ref-fulltext>WeMeReC Bulletin. Appropriate antibiotic use-whose responsibility? Available from: www.wemerec.org/Documents/Bulletins/AntibioBulletin2012Online.pdfNovember</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Antibiotic resistance - The need for global solutions</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84887627398</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Laxminarayan R.</ce:indexed-name><ce:surname>Laxminarayan</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Duse A.</ce:indexed-name><ce:surname>Duse</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Wattal C.</ce:indexed-name><ce:surname>Wattal</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lancet Infect Dis</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="13" issue="12"/><pagerange first="1057" last="1098"/></ref-volisspag></ref-info><ref-fulltext>Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013;13(12): 1057-98</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Antibiotic resistance in China - A major future challenge</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">58049161003</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Heddini A.</ce:indexed-name><ce:surname>Heddini</ce:surname></author><author seq="2"><ce:initials>O.</ce:initials><ce:indexed-name>Cars O.</ce:indexed-name><ce:surname>Cars</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Qiang S.</ce:indexed-name><ce:surname>Qiang</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Tomson G.</ce:indexed-name><ce:surname>Tomson</ce:surname></author></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="373" issue="9657"/><pagerange first="30"/></ref-volisspag></ref-info><ref-fulltext>Heddini A, Cars O, Qiang S, Tomson G. Antibiotic resistance in China-a major future challenge. Lancet 2009;373(9657):30</ref-fulltext></reference><reference id="10"><ref-info><refd-itemidlist><itemid idtype="SGR">0004271659</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>World Health Organisation</ce:indexed-name><ce:surname>World Health Organisation</ce:surname></author></ref-authors><ref-sourcetitle>WHO Global Strategy for Containment of Antimicrobial Resistance</ref-sourcetitle><ref-publicationyear first="2001"/><ref-website><ce:e-address type="email">www.who.int/csr/resources/publications/drugresist/en/EGlobal_Strat.pdf]</ce:e-address></ref-website><ref-text>Available from</ref-text></ref-info><ref-fulltext>World Health Organisation. WHO global strategy for containment of antimicrobial resistance. 2001. Available from: www.who. int/csr/resources/publications/drugresist/en/EGlobal-Strat.pdf]</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Outpatient antibiotic use in Europe and association with resistance: A cross-national database study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">13844254907</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Goossens H.</ce:indexed-name><ce:surname>Goossens</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Ferech M.</ce:indexed-name><ce:surname>Ferech</ce:surname></author><author seq="3"><ce:initials>R.</ce:initials><ce:indexed-name>Vander Stichele R.</ce:indexed-name><ce:surname>Vander Stichele</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Elseviers M.</ce:indexed-name><ce:surname>Elseviers</ce:surname></author></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="365" issue="9459"/><pagerange first="579" last="587"/></ref-volisspag></ref-info><ref-fulltext>Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9459):579-87</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77953917693</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Costelloe C.</ce:indexed-name><ce:surname>Costelloe</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Metcalfe C.</ce:indexed-name><ce:surname>Metcalfe</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Lovering A.</ce:indexed-name><ce:surname>Lovering</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>BMJ (Clinical Research Ed)</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="340"/><pagerange first="c2096"/></ref-volisspag></ref-info><ref-fulltext>Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ (Clinical research ed) 2010;340:c2096</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Antibiotic consumption and link to resistance</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">65449170027</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Goossens H.</ce:indexed-name><ce:surname>Goossens</ce:surname></author></ref-authors><ref-sourcetitle>Clin Microbiol Infect</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="15"/><pagerange first="12" last="15"/></ref-volisspag></ref-info><ref-fulltext>Goossens H. Antibiotic consumption and link to resistance. Clin Microbiol Infect 2009;15(Suppl 3)):12-15</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0032710846</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Cizman M.</ce:indexed-name><ce:surname>Cizman</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Pokorn M.</ce:indexed-name><ce:surname>Pokorn</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Seme K.</ce:indexed-name><ce:surname>Seme</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Eur J Clin Microbiol Infect Dis</ref-sourcetitle><ref-publicationyear first="1999"/><ref-volisspag><voliss volume="18" issue="7"/><pagerange first="522" last="524"/></ref-volisspag></ref-info><ref-fulltext>Cizman M, Pokorn M, Seme K, et al. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis 1999;18(7):522-4</ref-fulltext></reference><reference id="15"><ref-info><refd-itemidlist><itemid idtype="SGR">84924723860</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>Department of Health, Social Services and Public Safety Northern Ireland</ce:indexed-name><ce:surname>Department of Health, Social Services and Public Safety Northern Ireland</ce:surname></author></ref-authors><ref-sourcetitle>A Strategy for Changing Antimicrobial Resistance (STAR) 2012 to 2017</ref-sourcetitle><ref-website><ce:e-address type="email">www.dhsspsni.gov.uk/star-doc.pdf</ce:e-address></ref-website><ref-text>Available from</ref-text></ref-info><ref-fulltext>Department of Health, Social Services and Public Safety Northern Ireland. A strategy for changing antimicrobial resistance (STAR) 2012 to 2017. Available from: www.dhsspsni.gov.uk/star-doc.pdf</ref-fulltext></reference><reference id="16"><ref-info><refd-itemidlist><itemid idtype="SGR">0003779120</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>Standing Medical Advisory Committee</ce:indexed-name><ce:surname>Standing Medical Advisory Committee</ce:surname></author></ref-authors><ref-sourcetitle>The Path of Least Resistance</ref-sourcetitle><ref-website><ce:e-address type="email">http://antibioticaction.com/wp-content/uploads/2011/07/Standing-Medical-Advisory-Committee-Thepath-of-least-resistance-1998.pdf</ce:e-address></ref-website></ref-info><ref-fulltext>Standing Medical Advisory Committee. The Path of Least Resistance. http://antibioticaction. com/wp-content/uploads/2011/07/Standing-Medical-Advisory-Committee-Thepath-of-least-resistance-1998.pdf</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Strama - A Swedish working model for containment of antibiotic resistance</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">60549114599</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Molstad S.</ce:indexed-name><ce:surname>Molstad</ce:surname></author><author seq="2"><ce:initials>O.</ce:initials><ce:indexed-name>Cars O.</ce:indexed-name><ce:surname>Cars</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Struwe J.</ce:indexed-name><ce:surname>Struwe</ce:surname></author></ref-authors><ref-sourcetitle>Euro Surveill</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="13"/><pagerange first="46"/></ref-volisspag></ref-info><ref-fulltext>Molstad S, Cars O, Struwe J. Strama-a Swedish working model for containment of antibiotic resistance. Euro Surveill 2008; 13:46</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>European Surveillance of Antimicrobial Consumption (ESAC): Disease-specific quality indicators for outpatient antibiotic prescribing</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80052128361</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Adriaenssens N.</ce:indexed-name><ce:surname>Adriaenssens</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Tonkin-Crine S.</ce:indexed-name><ce:surname>Tonkin-Crine</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>BMJ Qual Saf</ref-sourcetitle><ref-publicationyear first="2011"/><ref-text>Epub ahead of print</ref-text></ref-info><ref-fulltext>Adriaenssens N, Coenen S, Tonkin-Crine S, et al. European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. BMJ Qual Saf 2011. [Epub ahead of print]</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>National campaigns to improve antibiotic use</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33646516859</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Goossens H.</ce:indexed-name><ce:surname>Goossens</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Guillemot D.</ce:indexed-name><ce:surname>Guillemot</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Ferech M.</ce:indexed-name><ce:surname>Ferech</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Eur J Clin Pharmacol</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="62" issue="5"/><pagerange first="373" last="379"/></ref-volisspag></ref-info><ref-fulltext>Goossens H, Guillemot D, Ferech M, et al. National campaigns to improve antibiotic use. Eur J Clin Pharmacol 2006;62(5): 373-9</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: Cluster randomised trial</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67650081378</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.W.</ce:initials><ce:indexed-name>Cals J.W.</ce:indexed-name><ce:surname>Cals</ce:surname></author><author seq="2"><ce:initials>C.C.</ce:initials><ce:indexed-name>Butler C.C.</ce:indexed-name><ce:surname>Butler</ce:surname></author><author seq="3"><ce:initials>R.M.</ce:initials><ce:indexed-name>Hopstaken R.M.</ce:indexed-name><ce:surname>Hopstaken</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>BMJ (Clinical Research Ed)</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="338"/><pagerange first="b1374"/></ref-volisspag></ref-info><ref-fulltext>Cals JW, Butler CC, Hopstaken RM, et al. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ (Clinical research ed) 2009;338:b1374</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: A multinational, cluster, randomised, factorial, controlled trial</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84884979664</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>P.</ce:initials><ce:indexed-name>Little P.</ce:indexed-name><ce:surname>Little</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Stuart B.</ce:indexed-name><ce:surname>Stuart</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Francis N.</ce:indexed-name><ce:surname>Francis</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="382" issue="9899"/><pagerange first="1175" last="1182"/></ref-volisspag></ref-info><ref-fulltext>Little P, Stuart B, Francis N, et al. Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial. Lancet 2013;382(9899):1175-82</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Analysis of the causes and consequences of decreased antibiotic consumption over the last 5 years in Slovenia</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">18844424751</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Cizman M.</ce:indexed-name><ce:surname>Cizman</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Srovin T.</ce:indexed-name><ce:surname>Srovin</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Pokorn M.</ce:indexed-name><ce:surname>Pokorn</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Antimicrob Chemother</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="55" issue="5"/><pagerange first="758" last="763"/></ref-volisspag></ref-info><ref-fulltext>Cizman M, Srovin T, Pokorn M, et al. Analysis of the causes and consequences of decreased antibiotic consumption over the last 5 years in Slovenia. J Antimicrob Chemother 2005;55(5):758-63</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>Ongoing programmes to reduce the high rate of antibiotic consumption in Serbia; Current situation and future direction</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84937144200</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Bajcetic M.</ce:indexed-name><ce:surname>Bajcetic</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Kalaba M.</ce:indexed-name><ce:surname>Kalaba</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Sipetic T.</ce:indexed-name><ce:surname>Sipetic</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Pharmacoepidemiol Drug Saf</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="21"/><pagerange first="98"/></ref-volisspag></ref-info><ref-fulltext>Bajcetic M, Kalaba M, Godman B, Sipetic T, et al. Ongoing programmes to reduce the high rate of antibiotic consumption in Serbia; current situation and future direction. Pharmacoepidemiol Drug Saf 2012;21(Suppl 3):98</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>Experimental and quasi-experimental designs for evaluating guideline implementation strategies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0033965927</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Grimshaw J.</ce:indexed-name><ce:surname>Grimshaw</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Campbell M.</ce:indexed-name><ce:surname>Campbell</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Eccles M.</ce:indexed-name><ce:surname>Eccles</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>Steen N.</ce:indexed-name><ce:surname>Steen</ce:surname></author></ref-authors><ref-sourcetitle>Fam Pract</ref-sourcetitle><ref-publicationyear first="2000"/><ref-volisspag><voliss volume="17"/><pagerange first="S11" last="16"/></ref-volisspag></ref-info><ref-fulltext>Grimshaw J, Campbell M, Eccles M, Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam Pract 2000;17 Suppl 1:S11-16</ref-fulltext></reference><reference id="25"><ref-info><refd-itemidlist><itemid idtype="SGR">33746598401</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>WHO</ce:indexed-name><ce:surname>WHO</ce:surname></author></ref-authors><ref-sourcetitle>Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2011</ref-sourcetitle><ref-publicationyear first="2013"/><ref-website><ce:e-address type="email">www.whocc.no/atc_ddd_index/</ce:e-address></ref-website><ref-text>WHO, Oslo. Available from</ref-text></ref-info><ref-fulltext>WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. WHO, Oslo. 2013. Available from: www.whocc.no/atc-ddd-index/</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">34548138984</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Campos J.</ce:indexed-name><ce:surname>Campos</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Ferech M.</ce:indexed-name><ce:surname>Ferech</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Lazaro E.</ce:indexed-name><ce:surname>Lazaro</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Antimicrob Chemother</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="60" issue="3"/><pagerange first="698" last="701"/></ref-volisspag></ref-info><ref-fulltext>Campos J, Ferech M, Lazaro E, et al. Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. J Antimicrob Chemother 2007;60(3):698-701</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>European Surveillance of Antimicrobial Consumption (ESAC): Outpatient antibiotic use in Europe (1997-2009)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">82055185445</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Adriaenssens N.</ce:indexed-name><ce:surname>Adriaenssens</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Versporten A.</ce:indexed-name><ce:surname>Versporten</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Antimicrob Chemother</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="66"/><pagerange first="vi3" last="12"/></ref-volisspag></ref-info><ref-fulltext>Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother 2011; 66(Suppl 6):vi3-12</ref-fulltext></reference><reference id="28"><ref-info><refd-itemidlist><itemid idtype="SGR">80055091440</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>R Project</ce:indexed-name><ce:surname>R Project</ce:surname></author></ref-authors><ref-sourcetitle>The R Project for Statistical Computing</ref-sourcetitle><ref-website><ce:e-address type="email">www.r-project.org/</ce:e-address></ref-website><ref-text>Available from</ref-text></ref-info><ref-fulltext>R Project. The R Project for Statistical Computing. Available from: www.r-project. org/</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>Pharmaceutical policies in European countries in response to the global financial crisis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">83055163268</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Vogler S.</ce:indexed-name><ce:surname>Vogler</ce:surname></author><author seq="2"><ce:initials>N.</ce:initials><ce:indexed-name>Zimmermann N.</ce:indexed-name><ce:surname>Zimmermann</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Leopold C.</ce:indexed-name><ce:surname>Leopold</ce:surname></author><author seq="4"><ce:initials>K.</ce:initials><ce:indexed-name>De Joncheere K.</ce:indexed-name><ce:surname>De Joncheere</ce:surname></author></ref-authors><ref-sourcetitle>Southern Med Rev</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="4" issue="2"/><pagerange first="69" last="79"/></ref-volisspag></ref-info><ref-fulltext>Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Rev 2011; 4(2):69-79</ref-fulltext></reference><reference id="30"><ref-info><ref-title><ref-titletext>Policies to enhance prescribing efficiency in europe: Findings and future implications</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79952781964</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="2"><ce:initials>W.</ce:initials><ce:indexed-name>Shrank W.</ce:indexed-name><ce:surname>Shrank</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Andersen M.</ce:indexed-name><ce:surname>Andersen</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Front Pharmacol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="1"/><pagerange first="141"/></ref-volisspag></ref-info><ref-fulltext>Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol 2010;1:141</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>Ongoing pharmaceutical reforms in France: Implications for key stakeholder groups</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">74249104458</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Sermet C.</ce:indexed-name><ce:surname>Sermet</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Andrieu V.</ce:indexed-name><ce:surname>Andrieu</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Appl Health Econ Health Policy</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="8" issue="1"/><pagerange first="7" last="24"/></ref-volisspag></ref-info><ref-fulltext>Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010;8(1): 7-24</ref-fulltext></reference><reference id="32"><ref-info><ref-title><ref-titletext>Soft regulations in pharmaceutical policy making: An overview of current approaches and their consequences</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84890797972</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Wettermark B.</ce:indexed-name><ce:surname>Wettermark</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Jacobsson B.</ce:indexed-name><ce:surname>Jacobsson</ce:surname></author><author seq="4"><ce:initials>F.M.</ce:initials><ce:indexed-name>Haaijer-Ruskamp F.M.</ce:indexed-name><ce:surname>Haaijer-Ruskamp</ce:surname></author></ref-authors><ref-sourcetitle>Appl Health Econ Health Policy</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="7" issue="3"/><pagerange first="137" last="147"/></ref-volisspag></ref-info><ref-fulltext>Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy 2009;7(3):137-47</ref-fulltext></reference><reference id="33"><ref-info><ref-title><ref-titletext>Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: Implications for the future</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80051726242</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.</ce:initials><ce:indexed-name>Voncina L.</ce:indexed-name><ce:surname>Voncina</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Strizrep T.</ce:indexed-name><ce:surname>Strizrep</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Expert Rev Pharmacoecon Outcomes Res</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="11" issue="4"/><pagerange first="469" last="479"/></ref-volisspag></ref-info><ref-fulltext>Voncina L, Strizrep T, Godman B, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2011;11(4):469-79</ref-fulltext></reference><reference id="34"><ref-info><ref-title><ref-titletext>Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84887216244</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="2"><ce:initials>I.</ce:initials><ce:indexed-name>Bishop I.</ce:indexed-name><ce:surname>Bishop</ce:surname></author><author seq="3"><ce:initials>A.E.</ce:initials><ce:indexed-name>Finlayson A.E.</ce:indexed-name><ce:surname>Finlayson</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Expert Rev Pharmacoecon Outcomes Res</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="13" issue="4"/><pagerange first="469" last="482"/></ref-volisspag></ref-info><ref-fulltext>Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82</ref-fulltext></reference><reference id="35"><ref-info><ref-title><ref-titletext>Different initiatives across Europe to enhance losartan utilisation post generics: Impact and implications</ref-titletext></ref-title><refd-itemidlist><itemid idtype="ARTNUM">219</itemid><itemid idtype="SGR">84907924559</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Moon J.</ce:indexed-name><ce:surname>Moon</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Petzold M.</ce:indexed-name><ce:surname>Petzold</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Front Pharmacol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="5"/><pagerange first="1" last="10"/></ref-volisspag></ref-info><ref-fulltext>Moon J, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications. Front Pharmacol 2014;5(Article 219):1-10</ref-fulltext></reference><reference id="36"><ref-info><ref-title><ref-titletext>Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84902068477</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Petzold M.</ce:indexed-name><ce:surname>Petzold</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Bennett K.</ce:indexed-name><ce:surname>Bennett</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>BMC Med</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="12" issue="1"/><pagerange first="98"/></ref-volisspag></ref-info><ref-fulltext>Godman B, Petzold M, Bennett K, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?: findings from across Europe and their implications. BMC Med 2014;12(1):98</ref-fulltext></reference><reference id="37"><ref-info><ref-title><ref-titletext>Pharmaceutical policy and the effects of the economic crisis: Lithuania</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">83055195072</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Garuoliene K.</ce:indexed-name><ce:surname>Garuoliene</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Alonderis T.</ce:indexed-name><ce:surname>Alonderis</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Marcinkevicius M.</ce:indexed-name><ce:surname>Marcinkevicius</ce:surname></author></ref-authors><ref-sourcetitle>EuroHealth</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="17"/><pagerange first="1" last="4"/></ref-volisspag></ref-info><ref-fulltext>Garuoliene K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. EuroHealth 2011;17:1-4</ref-fulltext></reference><reference id="38"><ref-info><ref-title><ref-titletext>What lessons can be learned from the launch of generic clopidogrel?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84881529271</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Baumgartel C.</ce:indexed-name><ce:surname>Baumgärtel</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="3"><ce:initials>R.</ce:initials><ce:indexed-name>Malmstrom R.</ce:indexed-name><ce:surname>Malmström</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>GaBI J</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="1" issue="2"/><pagerange first="58" last="68"/></ref-volisspag></ref-info><ref-fulltext>Baumgärtel C, Godman B, Malmström R, et al. What lessons can be learned from the launch of generic clopidogrel? GaBI J 2012; 1(2):58-68</ref-fulltext></reference><reference id="39"><ref-info><ref-title><ref-titletext>Dabigatran - A case history demonstrating the need for comprehensive approaches to optimize the use of new drugs</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84881534674</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.E.</ce:initials><ce:indexed-name>Malmstrom R.E.</ce:indexed-name><ce:surname>Malmstrom</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Diogene E.</ce:indexed-name><ce:surname>Diogene</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Frontiers in Pharmacology</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="4"/><pagerange first="39"/></ref-volisspag></ref-info><ref-fulltext>Malmstrom RE, Godman B, Diogene E, et al. Dabigatran-a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in pharmacology 2013;4:39</ref-fulltext></reference><reference id="40"><ref-info><ref-title><ref-titletext>Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: Changes seen and global implications</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650443213</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="2"><ce:initials>W.</ce:initials><ce:indexed-name>Shrank W.</ce:indexed-name><ce:surname>Shrank</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Andersen M.</ce:indexed-name><ce:surname>Andersen</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Expert Rev Pharmacoecon Outcomes Res</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="10" issue="6"/><pagerange first="707" last="722"/></ref-volisspag></ref-info><ref-fulltext>Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10(6):707-22</ref-fulltext></reference><reference id="41"><ref-info><ref-title><ref-titletext>Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84904756503</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Wettermark B.</ce:indexed-name><ce:surname>Wettermark</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Van Woerkom M.</ce:indexed-name><ce:surname>Van Woerkom</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Front Pharmacol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="5"/><pagerange first="106"/></ref-volisspag></ref-info><ref-fulltext>Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106</ref-fulltext></reference><reference id="42"><ref-info><refd-itemidlist><itemid idtype="SGR">79959679763</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Cizman M.</ce:indexed-name><ce:surname>Cizman</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Beovic B.</ce:indexed-name><ce:surname>Beovic</ce:surname></author></ref-authors><ref-sourcetitle>Prirocnik Za Ambulantno Predpisovanje Protimikrobnih Zdravil</ref-sourcetitle><ref-publicationyear first="2002"/><ref-text>Ljubljana: Arkadija</ref-text></ref-info><ref-fulltext>Cizman M, Beovic B. Prirocnik za ambulantno predpisovanje protimikrobnih zdravil. Ljubljana: Arkadija 2002</ref-fulltext></reference><reference id="43"><ref-info><ref-title><ref-titletext>European Antibiotic Awareness Day, 2008 - The first Europe-wide public information campaign on prudent antibiotic use: Methods and survey of activities in participating countries</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">70349250447</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Earnshaw S.</ce:indexed-name><ce:surname>Earnshaw</ce:surname></author><author seq="2"><ce:initials>D.L.</ce:initials><ce:indexed-name>Monnet D.L.</ce:indexed-name><ce:surname>Monnet</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Duncan B.</ce:indexed-name><ce:surname>Duncan</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Euro Surveill</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="14" issue="30"/><pagerange first="19280"/></ref-volisspag></ref-info><ref-fulltext>Earnshaw S, Monnet DL, Duncan B, et al. European Antibiotic Awareness Day, 2008-the first Europe-wide public information campaign on prudent antibiotic use: methods and survey of activities in participating countries. Euro Surveill 2009;14(30):19280</ref-fulltext></reference><reference id="44"><ref-info><refd-itemidlist><itemid idtype="SGR">84937138051</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>ZZZS</ce:indexed-name><ce:surname>ZZZS</ce:surname></author></ref-authors><ref-sourcetitle>Recept-The Bulletin on Drugs Covered by Compulsory Health Insurance</ref-sourcetitle><ref-publicationyear first="2013"/><ref-website><ce:e-address type="email">www.zzzs.si/zzzs/info/egradiva.nsf/o/FEAF7D3377DA0E13C1257A2C003406A3?OpenDocument</ce:e-address></ref-website><ref-text>Available from</ref-text></ref-info><ref-fulltext>ZZZS. Recept-The bulletin on drugs covered by Compulsory Health Insurance. 2013. Available from: www.zzzs.si/zzzs/info/egradiva.nsf/o/FEAF7D3377DA0E13C1257 A2C003406A3?OpenDocument</ref-fulltext></reference><reference id="45"><ref-info><refd-itemidlist><itemid idtype="SGR">84937143112</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>ZZZS</ce:indexed-name><ce:surname>ZZZS</ce:surname></author></ref-authors><ref-sourcetitle>Varna Raba Zdravil</ref-sourcetitle><ref-website><ce:e-address type="email">https://zavarovanec.zzzs.si/wps/portal/portali/azos/domov2013</ce:e-address></ref-website><ref-text>Available from</ref-text></ref-info><ref-fulltext>ZZZS. Varna raba zdravil. Available from: https://zavarovanec.zzzs.si/wps/portal/portali/azos/domov2013</ref-fulltext></reference><reference id="46"><ref-info><ref-title><ref-titletext>Quality Indicators as a Tool in Improving the Introduction of New Medicines</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84921263859</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.M.</ce:initials><ce:indexed-name>Campbell S.M.</ce:indexed-name><ce:surname>Campbell</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Diogene E.</ce:indexed-name><ce:surname>Diogene</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Basic Clin Pharmacol Toxicol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-text>Epub ahead of print</ref-text></ref-info><ref-fulltext>Campbell SM, Godman B, Diogene E, et al. Quality Indicators as a Tool in Improving the Introduction of New Medicines. Basic Clin Pharmacol Toxicol. 2014. [Epub ahead of print]</ref-fulltext></reference><reference id="47"><ref-info><ref-title><ref-titletext>Kakovost predpisovanja v druzinski medicini</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84880877153</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Bagari Bizjak N.</ce:indexed-name><ce:surname>Bagari Bizjak</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Furst J.</ce:indexed-name><ce:surname>Fürst</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Kramberger B.</ce:indexed-name><ce:surname>Kramberger</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Recept</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="9" issue="1"/><pagerange first="93" last="95"/></ref-volisspag></ref-info><ref-fulltext>Bagari Bizjak N, Fürst J, Kramberger B, et al. Kakovost predpisovanja v druzinski medicini. Recept 2011;9(1):93-5</ref-fulltext></reference><reference id="48"><ref-info><ref-title><ref-titletext>Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: Global relevance</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67651199598</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Wettermark B.</ce:indexed-name><ce:surname>Wettermark</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Hoffmann M.</ce:indexed-name><ce:surname>Hoffmann</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Expert Rev Pharmacoecon Outcomes Res</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="9" issue="1"/><pagerange first="65" last="83"/></ref-volisspag></ref-info><ref-fulltext>Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9(1):65-83</ref-fulltext></reference><reference id="49"><ref-info><ref-title><ref-titletext>European countries with small populations can obtain low prices for drugs: Lithuania as a case history</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79959269131</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Garuoliene K.</ce:indexed-name><ce:surname>Garuoliene</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Gulbinovic J.</ce:indexed-name><ce:surname>Gulbinovic</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Expert Rev Pharmacoecon Outcomes Res</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="11" issue="3"/><pagerange first="343" last="349"/></ref-volisspag></ref-info><ref-fulltext>Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res 2011;11(3):343-9</ref-fulltext></reference><reference id="50"><ref-info><ref-title><ref-titletext>Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79952173201</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Sakshaug S.</ce:indexed-name><ce:surname>Sakshaug</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Berg C.</ce:indexed-name><ce:surname>Berg</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Expert Rev Pharmacoecon Outcomes Res</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="11" issue="1"/><pagerange first="121" last="129"/></ref-volisspag></ref-info><ref-fulltext>Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res 2011;11(1): 121-9</ref-fulltext></reference><reference id="51"><ref-info><ref-title><ref-titletext>Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77149139476</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Wettermark B.</ce:indexed-name><ce:surname>Wettermark</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Godman B.</ce:indexed-name><ce:surname>Godman</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Neovius M.</ce:indexed-name><ce:surname>Neovius</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Health Policy</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="94" issue="3"/><pagerange first="221" last="229"/></ref-volisspag></ref-info><ref-fulltext>Wettermark B, Godman B, Neovius M, et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010;94(3):221-9</ref-fulltext></reference><reference id="52"><ref-info><ref-title><ref-titletext>Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">83555163959</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Pettersson B.</ce:indexed-name><ce:surname>Pettersson</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Hoffmann M.</ce:indexed-name><ce:surname>Hoffmann</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Wandell P.</ce:indexed-name><ce:surname>Wandell</ce:surname></author><author seq="4"><ce:initials>L.A.</ce:initials><ce:indexed-name>Levin L.A.</ce:indexed-name><ce:surname>Levin</ce:surname></author></ref-authors><ref-sourcetitle>Health Policy</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="104" issue="1"/><pagerange first="84" last="91"/></ref-volisspag></ref-info><ref-fulltext>Pettersson B, Hoffmann M, Wandell P, Levin LA. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 2012;104(1):84-91</ref-fulltext></reference><reference id="53"><ref-info><ref-title><ref-titletext>European Surveillance of Antimicrobial Consumption (ESAC): Outpatient quinolone use in Europe (1997-2009)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">82055183949</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Adriaenssens N.</ce:indexed-name><ce:surname>Adriaenssens</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Versporten A.</ce:indexed-name><ce:surname>Versporten</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Antimicrob Chemother</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="66"/><pagerange first="vi47" last="56"/></ref-volisspag></ref-info><ref-fulltext>Adriaenssens N, Coenen S, Versporten A, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009). J Antimicrob Chemother 2011; 66(Suppl 6):vi47-56</ref-fulltext></reference><reference id="54"><ref-info><refd-itemidlist><itemid idtype="SGR">84937144385</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:indexed-name>European Centre for Disease Prevention and Control</ce:indexed-name><ce:surname>European Centre for Disease Prevention and Control</ce:surname></author></ref-authors><ref-sourcetitle>Trend of Antimicrobial Consumption of Antibacterials for Systemic Use (ATC Group J01) in the Community (Primary Care Sector)</ref-sourcetitle><ref-website><ce:e-address type="email">www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/pages/trend-consumption-by-country.aspx</ce:e-address></ref-website><ref-text>Available from</ref-text></ref-info><ref-fulltext>European Centre for Disease Prevention and Control. Trend of antimicrobial consumption of antibacterials for systemic use (ATC group J01) in the community (primary care sector). Available from: www. ecdc.europa.eu/en/healthtopics/antimicrobial-resistance/esac-net-database/pages/trend-consumption-by-country.aspx</ref-fulltext></reference><reference id="55"><ref-info><ref-title><ref-titletext>Measurement units for antibiotic consumption in outpatients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84911029448</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Cizman M.</ce:indexed-name><ce:surname>Cizman</ce:surname></author></ref-authors><ref-sourcetitle>J Antimicrob Chemother</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="69" issue="10"/><pagerange first="2877" last="2878"/></ref-volisspag></ref-info><ref-fulltext>Cizman M. Measurement units for antibiotic consumption in outpatients. J Antimicrob Chemother 2014;69(10):2877-8</ref-fulltext></reference><reference id="56"><ref-info><ref-title><ref-titletext>Comment on: Measurement units for antibiotic consumption in outpatients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84929942082</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Coenen S.</ce:indexed-name><ce:surname>Coenen</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Bruyndonckx R.</ce:indexed-name><ce:surname>Bruyndonckx</ce:surname></author><author seq="3"><ce:initials>N.</ce:initials><ce:indexed-name>Hens N.</ce:indexed-name><ce:surname>Hens</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Antimicrob Chemother</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="69" issue="12"/><pagerange first="3445" last="3446"/></ref-volisspag></ref-info><ref-fulltext>Coenen S, Bruyndonckx R, Hens N, et al. Comment on: Measurement units for antibiotic consumption in outpatients. J Antimicrob Chemother 2014;69(12): 3445-6</ref-fulltext></reference><reference id="57"><ref-info><ref-title><ref-titletext>Behaviour change interventions to promote prescribing of generic drugs: A rapid evidence synthesis and systematic review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="ARTNUM">e004623</itemid><itemid idtype="SGR">84901497250</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Moe-Byrne T.</ce:indexed-name><ce:surname>Moe-Byrne</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Chambers D.</ce:indexed-name><ce:surname>Chambers</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Harden M.</ce:indexed-name><ce:surname>Harden</ce:surname></author><author seq="4"><ce:initials>C.</ce:initials><ce:indexed-name>McDaid C.</ce:indexed-name><ce:surname>McDaid</ce:surname></author></ref-authors><ref-sourcetitle>BMJ Open</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="4" issue="5"/></ref-volisspag></ref-info><ref-fulltext>Moe-Byrne T, Chambers D, Harden M, McDaid C. Behaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic review. BMJ open 2014;4(5):e004623</ref-fulltext></reference><reference id="58"><ref-info><ref-title><ref-titletext>Systematic review of factors affecting pharmaceutical expenditures</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84900803895</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.A.</ce:initials><ce:indexed-name>Mousnad M.A.</ce:indexed-name><ce:surname>Mousnad</ce:surname></author><author seq="2"><ce:initials>A.A.</ce:initials><ce:indexed-name>Shafie A.A.</ce:indexed-name><ce:surname>Shafie</ce:surname></author><author seq="3"><ce:initials>M.I.</ce:initials><ce:indexed-name>Ibrahim M.I.</ce:indexed-name><ce:surname>Ibrahim</ce:surname></author></ref-authors><ref-sourcetitle>Health Policy</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="116" issue="2-3"/><pagerange first="137" last="146"/></ref-volisspag></ref-info><ref-fulltext>Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health Policy 2014;116(2-3):137-46</ref-fulltext></reference><reference id="59"><ref-info><ref-title><ref-titletext>Predpisovanje protimikrobnih zdravil v domovih za ostarele. Infektoloski simpozij 2010 Ljubljana</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84937138938</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Lejko-Zupanc T.</ce:indexed-name><ce:surname>Lejko-Zupanc</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Cizman M.</ce:indexed-name><ce:surname>Cizman</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Knez L.</ce:indexed-name><ce:surname>Knez</ce:surname></author></ref-authors><ref-sourcetitle>Sekcija Za Kemoterapijo J</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><pagerange first="105" last="114"/></ref-volisspag></ref-info><ref-fulltext>Lejko-Zupanc T, Cizman M, Knez L. Predpisovanje protimikrobnih zdravil v domovih za ostarele. Infektoloski simpozij 2010 Ljubljana. Sekcija za kemoterapijo J 2010;105-14</ref-fulltext></reference><reference id="60"><ref-info><ref-title><ref-titletext>Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane effective practice and organization of care review group</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0032528707</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.A.</ce:initials><ce:indexed-name>Bero L.A.</ce:indexed-name><ce:surname>Bero</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Grilli R.</ce:indexed-name><ce:surname>Grilli</ce:surname></author><author seq="3"><ce:initials>J.M.</ce:initials><ce:indexed-name>Grimshaw J.M.</ce:indexed-name><ce:surname>Grimshaw</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>BMJ (Clinical Research Ed)</ref-sourcetitle><ref-publicationyear first="1998"/><ref-volisspag><voliss volume="317" issue="7156"/><pagerange first="465" last="468"/></ref-volisspag></ref-info><ref-fulltext>Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ (Clinical research ed) 1998;317(7156):465-8</ref-fulltext></reference><reference id="61"><ref-info><ref-title><ref-titletext>Using clinical evidence</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035799060</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Barton S.</ce:indexed-name><ce:surname>Barton</ce:surname></author></ref-authors><ref-sourcetitle>BMJ (Clinical Research Ed)</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="322" issue="7285"/><pagerange first="503" last="504"/></ref-volisspag></ref-info><ref-fulltext>Barton S. Using clinical evidence. BMJ (Clinical research ed) 2001;322(7285):503-4</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>